Clinical Cancer Research, Vol 3, Issue 6 891-899, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients

E Gamelin, AL Bouil, M Boisdron-Celle, A Turcant, R Delva, A Cailleux, A Krikorian, S Brienza, E Cvitkovic, J Robert, F Larra and P Allain
Department of Medical Oncology and Clinical Pharmacology, Centre Paul Papin, Centre Regional de Lutte Contre le Cancer, 49033 Angers Cedex.

The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer. Oxaliplatin was administered by i. v. infusion (130 mg/m2) over 2 h every 3 weeks, and 5-fluorouracil and leucovorin were administered weekly. A very sensitive method, inductively coupled plasma-mass spectrometry, allowed for the determination of total plasma and ultracentrifugable (UC) and RBC platinum levels on day 1, at 0, 2, and 5 h, and on days 8, 15, and 22. Sixteen patients underwent three or more courses, and six of them underwent six or more courses. The platinum concentration curves were quite similar from one course to another, with a high peak value 2 h after administration (day 1, Cmax = 3201 +/- 609 microgram/liter) and a rapid decrease (day 8, 443 +/- 99 microgram/liter). Cmax of both total and UC platinum levels in plasma remained unchanged throughout the treatment. The mean total platinum half-life in plasma was 9 days. We found residual levels of total platinum on day 22 (161 +/- 45 microgram/liter), but we observed no significant accumulation for the four first cycles (P = 0.57). In contrast, platinum accumulated significantly in RBCs after three courses (+91% at day 22 of the third cycle versus day 22 of the first cycle, P = 0.000018), and its half-life there was equivalent to that of RBCs. The patterns of UC and total platinum concentration curves were very similar and correlated significantly (P < 10(-6)) at all sampling times. The mean UC:total platinum ratio was 15% at day 1 and 5% at days 8, 15, and 22 in the 3-week treatment course. Unlike cisplatin, which rapidly accumulates in plasma as both free and bound platinum, oxaliplatin does not accumulate in plasma, but it does accumulate in RBCs, after repeated cycles at the currently recommended dose (130 mg/m2) and schedule of administration (every 3 weeks).

This article has been cited by other articles:

				L. Gamelin, O. Capitain, A. Morel, A. Dumont, S. Traore, L. B. Anne, S. Gilles, M. Boisdron-Celle, and E. Gamelin Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway Clin. Cancer Res., November 1, 2007; 13(21): 6359 - 6368. [Abstract] [Full Text] [PDF]

				C. H. Takimoto, M. A. Graham, G. Lockwood, C. M. Ng, A. Goetz, D. Greenslade, S. C. Remick, S. Sharma, S. Mani, R. K. Ramanathan, et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function Clin. Cancer Res., August 15, 2007; 13(16): 4832 - 4839. [Abstract] [Full Text] [PDF]

				M. A. Moufarij, D. Sampath, M. J. Keating, and W. Plunkett Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal Blood, December 15, 2006; 108(13): 4187 - 4193. [Abstract] [Full Text] [PDF]

				J. Peng, R. Mandal, M. Sawyer, and X.-F. Li Characterization of Intact Hemoglobin and Oxaliplatin Interaction by Nanoelectrospray Ionization Tandem Mass Spectrometry Clin. Chem., December 1, 2005; 51(12): 2274 - 2281. [Abstract] [Full Text] [PDF]

				J. L. Misset, E. Gamelin, M. Campone, S. Delaloge, J. E. Latz, L. Bozec, and P. Fumoleau Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors Ann. Onc., July 1, 2004; 15(7): 1123 - 1129. [Abstract] [Full Text] [PDF]

				F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels J Neurophysiol, May 1, 2001; 85(5): 2293 - 2297. [Abstract] [Full Text] [PDF]

				P. Allain, O. Heudi, A. Cailleux, A. Le Bouil, F. Larra, M. Boisdron-Celle, and E. Gamelin Early Biotransformations of Oxaliplatin after Its Intravenous Administration to Cancer Patients Drug Metab. Dispos., November 1, 2000; 28(11): 1379 - 1384. [Abstract] [Full Text]

				M. A. Graham, G. F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas, and E. Gamelin Clinical Pharmacokinetics of Oxaliplatin: A Critical Review Clin. Cancer Res., April 1, 2000; 6(4): 1205 - 1218. [Abstract] [Full Text]

				W. Kern, J. Braess, B. Bottger, C. C. Kaufmann, W. Hiddemann, and E. Schleyer Oxaliplatin Pharmacokinetics during a Four-Hour Infusion Clin. Cancer Res., April 1, 1999; 5(4): 761 - 765. [Abstract] [Full Text] [PDF]